Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Gains from Sales and Divestitures (2023 - 2024)

OptimizeRx's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $295018.0 for Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures rose 107.97% year-over-year to $295018.0; the TTM value through Dec 2024 reached $295018.0, up 107.97%, while the annual FY2024 figure was $295018.0, 107.97% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2024 was $295018.0 at OptimizeRx, up from $141859.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $295018.0 in Q4 2024 and bottomed at $141859.0 in Q4 2023.